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Objective: The objective of this study was to investigate the effect of nitric oxide on
the recovery of right heart function under global ischemia with a continuous-flow
biventricular assist device support.
Methods: Fifteen piglets were divided into three groups: continuous-flow biven-
tricular assist support only (control group), global ischemia with continuous-flow
biventricular assist support (ischemia only group), and global ischemia with con-
tinuous-flow biventricular assist support plus nitric oxide inhalation (nitric oxide
group). Two continuous-flow pumps were used as left and right ventricular assist
devices. In the ischemic groups (ischemia only group and nitric oxide group), global
ischemia was induced for 30 minutes and followed by a 6-hour reperfusion period;
the nonischemic control group underwent a 6-hour perfusion period only. The left
ventricular assist device was driven at a flow rate of more than 75 to 80 mL/(min 
kg). The right ventricular assist device was driven so as to sustain the left ventricular
assist device flow, and the animal was weaned from it in accordance with the
objective of cardiac recovery.
Results: Mean pulmonary arterial pressure remained low in the nitric oxide group
(mean 23 mm Hg), whereas it rose from 19.9 mm Hg to 39.3 mm Hg in the ischemia
group and to 26.2 mm Hg in the control group. Mixed venous saturation was
maintained at more than 60% in all cases. Although no piglets in the ischemia group
were able to survive without continuous-flow biventricular assist support, the right
ventricular assist device flow ratio (device flow/total systemic flow) in the nitric
oxide group could be reduced in all cases, and it was possible to wean the piglets
from right ventricular assist device support in 4 of 5 cases.
Conclusion: Inhalation of 40-ppm nitric oxide enabled smoother maintenance of the
left ventricular assist device flow and prompted the weaning from right ventricular
assist device support on continuous-flow biventricular assist.
Aventricular assist device (VAD) is often used to rescue patientswith severe and uncontrollable heart failure.1 Typically, a leftVAD (LVAD) is used for these patients, although biventricularmechanical assistance may be necessary during the early phase insome cases. Thus for many patients the need for right ventricularassistance is temporary. Therefore a management strategy for
biventricular assistance that includes weaning from a right VAD (RVAD) is im-
portant. Few investigators have tried to determine management strategies for a
continuous-flow biventricular assist device (CFBVAD), however, because the
VADs commonly used clinically are based on pulsatile pumps.
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Notably, the use of inhaled nitric oxide is attractive for
its effect on right ventricular recovery through induction of
pulmonary arterial dilatation,2-5 and it is used in combina-
tion with mechanical ventricular assistance in many medical
facilities.6-9 The objective of this study was to investigate
the effect of nitric oxide on the recovery of right heart
function under global ischemia as a model of severe heart
failure that needs LVAD support and temporal RVAD sup-
port, with CFBVAD support.
Materials and Methods
Animals and Animal Care
Fifteen male piglets (32-43.5 kg, mean 37.9 kg) were used. All
studies were conducted in the Experimental Animal Center of
Miyazaki Medical College, and all experimental protocols were
approved in advance by the animal care and use committee of this
institution. The study complied with the “Principles of Laboratory
Animal Care” developed by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the National Institutes of Animal Resources,
National Research Council, and published by the National Acad-
emy Press, revised 1996.
Preparation
Piglets were treated in advance with an intramuscular injection of
a cocktail of ketamine hydrochloride (0.5 mg/kg) and atropine
sulfate (0.5 mg). After induction of anesthesia by halothane, tra-
cheotomy was performed. During surgery, anesthesia was main-
tained under mechanical ventilation with oxygen, nitrous oxide,
and 0.5% to 2.0% halothane; the fraction of inspired oxygen was
maintained at 0.5 to 0.8. A venous line was established for con-
tinuous injection of Ringer’s lactate solution (10-15 mL/[kg 
min]). Two catheters were placed for right ventricular pressure
(RVP) and right atrial pressure (RAP) through the left internal
thoracic vein, and an arterial catheter was placed in the internal
thoracic artery for aortic pressure (AoP).
Technique
After systemic heparinization (100 U/kg bolus and 60-100 U/h
continuous injection to maintain the activated coagulation time at
150-250 seconds), an LVAD and an RVAD were placed through
a left thoracotomy. The inflow cannula of the LVAD was im-
planted into the left ventricle through the left atrium, and the
outflow cannula was connected to a T-shaped glass tube implanted
into the descending aorta. The inflow cannula of the RVAD was
implanted into the right atrium, and the outflow cannula was
connected to a conduit that was anastomosed to the pulmonary
trunk. A catheter for left atrial pressure (LAP) and left ventricular
pressure (LVP) was incorporated into the LVAD inflow conduit,
and a catheter for pulmonary arterial pressure (PAP) was inserted
into the pulmonary trunk through the RVAD outflow conduit. An
ultrasonic flow probe (T201; Transonic Systems, Inc, Ithaca, NY)
was placed around the base of the ascending aorta to monitor
cardiac output (CO).
Delivery of Nitric Oxide
The stock gas (with a premixed concentration of 200-ppm nitric
oxide in nitrogen) was supplied and delivered through one arm of
a Y-connector that was connected directly to the endotracheal tube,
where it was diluted with oxygen and anesthetic gas. The endo-
tracheal nitric oxide concentration was maintained at 40 ppm by
flow control.
The exhaled gas was dehumidified using silica gel; the nitrogen
oxide was absorbed onto soda lime and activated charcoal before
exhaustion. At indeterminate time, nitric oxide concentration was
confirmed in comparison with the determination curve, which was
previously measured with various gas concentrations, by nitric
oxide analyzer (ENO-20; EICOM Corp, Kyoto, Japan).
Continuous-Flow Biventricular Assist Device Control
Method
Our control strategy was previously reported in detail.11-15 We set
LVAD pump speed within the total assist, nonsucking range (safe
range), with a target flow rate of 50 to 75 mL/(kg  min) (75
mL/[kg  min], ideally) to obtain the same flow in each group.
Although this flow rate represents a slightly lower than usual level
of support, it was determined on consideration of the mixed venous
oxygen saturation (60%) in the ischemic group, which was
barely able to maintain such a flow rate in this series. For consis-
tency, the other groups were required to have no more than this
flow. The RVAD speed was kept within the safe range, with
RVAD flow controlled at the minimum level able to maintain the
LVAD target flow.
Protocol
After the CFBVAD was in place, LVAD support was started,
followed by induction of global ischemia by clamping of the base
of the ascending aorta for 30 minutes. When cardiac dysfunction
developed and the flow rate decreased, RVAD support was started.
Nitrogen inhalation (control and ischemia groups) or 40-ppm nitric
oxide inhalation (nitric oxide group) was performed, at the same
flow rate, on commencement of RVAD support (Figure 1). If no
cardiac recovery had appeared by 2 hours after reperfusion, elec-
tric defibrillation was performed (10-60 J). In addition, if no
response was achieved with 60-J stimulation, a retry was per-
formed after 15 minutes.
Hemodynamic data were collected every 5 minutes after the
start of LVAD support. To detect native cardiac function, data
were sampled with the pumps transiently stopped for 30 seconds,
at 1-hour intervals after unclamping. All animals were killed under
deep anesthesia and potassium chloride injection after more than 6
hours of observation. To maintain the preload of RVAD, Ringer’s
lactate solution was injected at the rate of 120 mL/h in all groups,
to make the conditions of preload the same with each animal.
Sampling and Recording of Data
AoP, PAP, LVP, LAP, RVP, RAP, pump speeds (LVAD and
RVAD), CO, and pump flow rates were measured. Left and right
ventricular instantaneous pressures (LV dp/dt and RV dp/dt, re-
spectively) and left and right ventricular end-diastolic pressures
(LVEDP and RVEDP, respectively) without biventricular VAD
(BVAD) support were sampled during transient CFBVAD inacti-
vation by clamping the outflow cannulas, with derived quantities
calculated from the waveforms. Blood gas values (arterial and
venous) were measured every 30 minutes.
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All values were digitized by a personal computer (EN6450;
COMPAQ Japan, Tokyo, Japan) running a data collection program
(Labview 5.0; National Instruments, Austin, Tex). Pressures were
recorded through a polygraph (EP1102; NEC, Tokyo, Japan),
whereas motor current and pump speed were entered directly.
The circulating blood was sampled every hour to determine the
cell count and the blood chemistry profile as follows: blood urea
nitrogen and creatinine were used as parameters to assess renal
function; alanine aminotransferase and total bilirubin values were
used to assess liver injury; creatine phosphokinase MB isoenzyme
and troponin T were used to assess myocardial injury; free hemo-
globin was used to assess hemolysis; aspartate aminotransferase
and lactate dehydrogenase were used to assess non-specific cell
injury; and methemoglobin was used to assess red blood cell injury
by nitric oxide.
Lung tissue was collected to assess lung edema. Tissue resected
from the apex was fixed by formalin and microscopic assessment
was performed after hematoxylin and eosin staining. For another
tissue sample from the lower lobe, the wet/dry ratio was deter-
mined from the masses before and after drying under the condition
of 100 for 72 hours.16
Statistical Analysis
All results were expressed as means and standard deviations and
analyses of data were performed with commercial statistical soft-
ware (STATVIEW 5.0; SAS Institute, Inc, Cary, NC). Analysis of
variance was used to compare measurements at baseline with those
taken during the postreperfusion phase. The Fisher protected least
significant difference was used to test the significance of differ-
ences.
Results
Four phases determined by pump flow and cardiac condition
were observed, especially in the nitric oxide group (Figure
2, C). The first observation phase was during ventricular
fibrillation (Vf phase); during this phase no native CO was
seen. The second observation phase followed electric defi-
brillation, in which low native output was seen (weak con-
traction phase). The third phase was characterized by an
excess of left pump flow (LPF) over right pump flow (RPF;
RVAD weaning phase). The last observation phase took
place after RVAD support was stopped (no-RVAD phase).
During global ischemia and early after reperfusion (effec-
tively the Vf phase), native beating disappeared and CO was
almost zero, so that the animal could not live without
CFBVAD support. In this phase the ischemia group re-
quired that LVAD speed be increased to the maximum
possible before sucking occurred, and to secure sufficient
LPF it needed higher RPF to provide sufficient preload to
the LVAD because, on measurement, RPF appeared to
exceed LPF.
Electric defibrillation was performed 2 hours after reper-
fusion in 9 of 10 cases in the ischemic groups (5 in ischemia
group, 4 in nitric oxide group). As the cardiac function
Figure 1. Protocol of this study. After CFBVAD was in place, global ischemia was induced by clamping base of
ascending aorta for 30 minutes in ischemia groups (group I) and nitric oxide group (group N). Nitrogen (control
group [group C] and ischemia group) or 40-ppm nitric oxide (NO, nitric oxide group) inhalation was administered,
at same flow rate, when RVAD support was initiated. Hemodynamic data were collected every 5 minutes after start
of LVAD support. In addition, blood was sampled every hour for blood chemistry analysis.
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Figure 2. Time course of pump flow in each group. A, Control group (group C). B, Ischemia group (group I). C, Nitric
oxide group (group N).
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gradually recovered during this procedure, the relative mag-
nitude of pump flow rates was able to reverse (LPF greater
than RPF). By controlling a CFBVAD as described previ-
ously, RPF was decreased gradually without loss of LPF,
and the piglets were weaned from the RVAD support almost
automatically in all cases in the nitric oxide group.
In the ischemia group, the Vf phase and the weak con-
traction phase were observed but the other phases were not
because of poor recovery of cardiac function. In the control
group, in which ischemia was not induced, only the RVAD
weaning phase and the no-RVAD phase were observed
(Figure 2 A and B).
Because significant reddening of the lung was observed
just after global ischemia and RVAD support in the isch-
emia group, the existence of lung congestion was suspected.
This color change improved slightly during the 6 hours of
observation but did not fade completely. Such color change
was rarely observed in the control and nitric oxide groups.
Hemodynamic Parameters
The time courses of the hemodynamic parameters are
shown in Table 1 and Figure 3. AoP with CFBVAD support
was maintained at 56.0  11.1 mm Hg in the control group,
54.5  11.4 mm Hg in the ischemia group, and 60.5  7.9
mm Hg in the nitric oxide group, all of which values were
similar to the values before support (56.0  11.1 mm Hg,
55.7  10.6 mm Hg, and 59.4  7.1 mm Hg, respectively).
There was no significant difference between the groups at
any time.
Although its initial value was the same, PAP rose during
the process of equipping BVAD, in each group (control
TABLE 1. Hemodynamic canges during BVAD support
Group BVAD on 1 h 2 h 3 h 6 h
On-AoP (mm Hg)
Control 51.2 12.5 56.0 5.4 54.0 6.5 51.9 6.6 64.2 14.5
Ischemia 50.2 9.4 56.0 10.7 55.3 9.4 51.3 7.5 51.2 11.3
Nitric oxide 57.5 10.9 57.2 8.9 60.0 9.4 59.5 7.5 60.5 15.7
On-LVP (mm Hg)
Control 26.4 15.2 19.9 5.9 16.5 5.0 11.0 3.2 26.1 8.4
Ischemia 19.4 8.4 12.6 14.5 14.5 10.6 14.7 11.6 13.5 10.2*
Nitric oxide 13.4 6.5 15.6 7.9 16.0 4.0 15.3 4.0 23.4 3.9
On-LAP (mm Hg)
Control 9.0 2.7 7.6 3.5 6.4 2.2 6.4 2.2 8.7 1.8
Ischemia 4.3 3.9 14.1 10.8 12.4 11.0 10.0 9.7 11.4 8.6
Nitric oxide 8.2 2.1 8.8 3.9 10.2 2.9 9.8 6.5 10.7 3.3
On-PAP (mm Hg)
Control 25.8 8.2 26.2 6.1 28.4 9.2 27.8 9.7 27.9 3.1
Ischemia 25.5 10.7 38.8 6.2† 7.8 3.2† 38.4 5.5† 38.6 8.4†
Nitric oxide 25.3 6.2 23.3 2.9* 5.1 2.3* 23.7 6.0* 24.9 6.4*
On-RVP (mm Hg)
Control 14.5 2.5 15.7 3.3 15.4 2.7 16.0 5.3 13.8 6.5
Ischemia 13.6 2.0 7.5 2.7† 7.4 2.8† 9.2 2.6† 7.8 2.7†
Nitric oxide 13.5 2.1 7.5 6.6† 7.1 6.4† 11.1 4.7 19.0 3.6*
On-RAP (mm Hg)
Control 3.3 2.6 3.1 2.2 3.5 1.6 4.1 2.1 7.9 2.7
Ischemia 4.4 1.8 2.0 1.5 3.7 1.3 4.5 2.5 5.2 6.0
Nitric oxide 3.4 1.6 3.2 1.5 2.8 1.9 2.6 1.9 7.1 1.9
LPF (L/min)
Control 2.2 0.6 2.5 0.5 2.1 0.5 2.0 0.4 2.4 0.3
Ischemia 2.1 0.5 2.3 0.6 2.6 1.1 2.4 0.9 2.3 0.9
Nitric oxide 2.5 0.3 2.4 0.3 2.3 0.4 2.3 0.4 2.4 0.3
Systemic vascular resistance (dyne  s/cm5)
Control 1937.7 216.6 1693.4 298.3 1858.5 318.0 1569.5 430.9 1789.4 242.1
Ischemia 1738.2 390.9 1881.0 190.6 1901.6 619.0 1696.5 457.2 1905.7 698.9
Nitric oxide 1932.7 535.7 1743.7 139.0 1970.1 147.4 1957.6 94.6 1681.2 615.2
PVR (dyne  s/cm5)
Control 679.4 335.9 612.8 270.7 863.7 443.2 941.9 400.1 646.8 201.6
Ischemia 702.8 463.9 867.0 325.8 948.9 361.6 1022.7 282.1 1097.9 445.2†
Nitric oxide 539.7 213.3 519.3 164.5 535.7 174.3 560.8 274.1* 453.5 211.8*
*P  .05 versus ischemia alone group.
†P  .05 versus control group.
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25.8 8.2 mm Hg, ischemia 25.5 10.7 mm Hg, and nitric
oxide 25.3 6.2 mm Hg). In the control group, PAP during
reperfusion was maintained at an average of 26.2 6.1 mm
Hg. In the ischemia group, it rose to 38.8 6.2 mm Hg after
1 hour of reperfusion and was maintained at an average of
39.2  6.4 mm Hg during 6 hours of reperfusion. In the
nitric oxide group, PAP rose to 23.2  6.1 mm Hg in the
first hour of reperfusion and was maintained at an average
of 24.2  4.9 mm Hg during the 6-hour reperfusion. After
6 hours of reperfusion, a significant difference in PAP was
detected between the groups (control vs ischemia P 
.0001, ischemia vs nitric oxide P  .0001, and control vs
nitric oxide P  .005; Figure 3, A).
Pulmonary vascular resistance (PVR) gradually in-
creased after global ischemia and 6-hour reperfusion, from
702.8  463.9 dyne  s  cm5 at BVAD equipping period
to 994.9 410.2 dyne  s  cm5 in the ischemia group. That
of the nitric oxide group decreased, from 539.7  213.3
dyne  s  cm5 to 366.1 94.5 dyne  s  cm5 after 6 hours
of nitric oxide inhalation (Figure 3, B).
Pump flow (2.2  0.4 L/min in the control group, 2.4 
0.8 L/min in the ischemia group, and 2.4  0.3 L/min in
nitric oxide group) remained at 80% to 85% of basal CO
(2.7  0.7 L/min, 2.7  0.5 L/min, and 2.9  0.5 L/min,
respectively). To maintain the target flow in the ischemia
group, however, it was necessary to increase the pump
speed to the vicinity of the point at which sucking occurred,
to maximize LVAD and RVAD flow rate.
The time courses of native cardiac function estimated
during transient CFBVAD inactivation and the support rate
of CFBVAD are shown in Table 2 and Figure 4. CO rarely
recovered after global ischemia in the ischemia group. In
contrast, whereas CO in the nitric oxide group showed a
decline similar to that in the ischemia group at the global
ischemia phase, this was only temporary, and it then grad-
ually increased with reperfusion until recovery was almost
that of the control group at 5.5 hours after reperfusion
(Figure 4, A).
Reduced LV dp/dt, caused by global ischemia, showed a
step increase after defibrillation in the ischemic groups.
Although in the ischemia group it gradually decreased
through reperfusion, in the nitric oxide group it increased to
about 80% of baseline or that of the control group (P .05;
Figure 4, B). LVEDP in both ischemic groups declined from
global ischemia to defibrillation and increased after defibril-
lation. The rate of decline was smaller in the nitric oxide
group, but no significant difference was observed when
compared with the ischemia group (Figure 4, C). RV dp/dt
showed an increase-and-decrease pattern that was similar to
that of LV dp/dt (P  .05; Figure 4, D). RVEDP in both
ischemic groups declined from global ischemia to defibril-
lation and increased after the defibrillation. The rate of
decline was smaller in the nitric oxide group, but no signif-
icant difference was observed when compared with the
ischemia group (Figure 4, E).
The consumption and supply of oxygen are shown in
Table 3. In all groups, mixed venous oxygen saturation
(SvO2), which was relied on as a parameter for systemic
oxygen supply, was maintained at greater than 60%, this
being considered as indicative that pump flow was sufficient
for systemic oxygen demand, in all phases. However, to
keep the SvO2 above 60%, the fraction of inspired oxygen
had to be raised to 0.6  1.0 in the ischemia group, despite
the requirement of the protocol for the fraction of inspired
oxygen of the nitric oxide group to be 0.5.
In addition, although spontaneous micturition was not
observed in the ischemia group, it was observed in all cases
in the nitric oxide group at 4.5 to 5.5 hours after reperfusion.
Blood Chemistry Data
Blood urea nitrogen, creatinine, C3a, aspartate aminotrans-
ferase, and lactate dehydrogenase increased gradually in all
groups, but no significant differences were observed be-
tween groups. Alanine aminotransferase and total bilirubin
Figure 3. Time courses of on-PAP (A) and PVR (B). Inhalation of
40-ppm nitric oxide during CFBVAD support reduced PVR and PAP
immediately in nitric oxide group (group N), whereas it remained
higher level in ischemia group (group I). Group C, Control group.
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values remained within the normal range in all groups,
suggesting that no liver dysfunction existed.
Creatine phosphokinase MB isoenzyme and troponin T
increased in each group just after the BVAD was implanted.
Although these remained almost constant throughout the
reperfusion time in the control group, they gradually
increased in the ischemic groups (ischemia and nitric
oxide groups). Thus the degree of myocardial damage
induced by myocardial ischemia was similar in both
ischemic groups.
Free hemoglobin, which was used as a parameter for
hemolysis, increased in each group, the value for the nitric
oxide group lying between those of the control and ischemia
groups. However, although there was a significant differ-
ence between the ischemia group and the control group,
differences between the nitric oxide group and the others
were not significant.
Methemoglobin remained less than 1.2 mg/dL (10%-
15% of hemoglobin value) in all cases in the nitric oxide
group.
Pathologic Findings in Lung
As a matter of convenience, pathologic findings in resected
lung tissue were classified into three degrees: mild, no
edema or only intravascular congestion in the section; mod-
erate, interstitial edema in the section; and severe, intersti-
tial edema and intra-alveolar effusion or hemorrhage the
section. Whereas almost normal findings were made in the
control group (3 mild and 2 moderate), frank interstitial
edema was observed in the ischemia group (1 mild, 2
moderate, and 2 severe). On the other hand, despite isch-
emic conditions, no interstitial edema was found in the nitric
oxide group (2 mild and 3 moderate).
TABLE 2. Time courses of native cardiac function
Group Baseline BVAD on 1 h 2 h 3 h 6 h
CO (L/min)
Control 2.7 0.7 2.4 0.4 1.9 0.4 1.4 0.2 0.9 0.5 1.5 0.8
Ischemia 2.7 0.6 2.1 0.5 — — 0.1 0.1* 0.3 0.5*
Nitric oxide 3.0 0.8 2.4 0.3 0.5 0.9 0.2 0.4 0.7 0.3† 1.3 0.2†
LVEDP (mm Hg)
Control 10.3 4.1 10.4 2.4 10.6 0.0 12.1 0.7 12.0 1.4 14.2 2.3
Ischemia 13.1 2.8 1.5 7.7 — — 11.1 10.5 12.6 11.7
Nitric oxide 11.7 4.2 2.8 8.6 6.2 10.7 8.5 11.2 16.1 1.9 20.0 2.6
RVEDP (mm Hg)
Control 6.8 0.1 6.5 0.2 6.3 0.4 8.2 0.5 8.1 4.2 7.0 1.8
Ischemia 7.0 2.8 3.0 6.8 — — 11.6 4.2 8.2 7.5
Nitric oxide 4.0 4.3 0.2 7.8 3.3 5.7 3.6 6.2 6.8 1.1 7.1 4.4
LV dp/dt (mm Hg/s)
Control — 495.5 342.4 — 427.5 128.8 356.3 145.9 588.0 211.5
Ischemia — 483.5 185.1 — — 149.7 95.9 82.5 100.6*
Nitric oxide — 709.3 80.8 — 92.1 159.6 215.6 131.8 461.6 58.3
RV dp/dt (mm Hg/s)
Control — 256.5 91.0 — 274.5 17.9 257.2 27.0 260.5 72.3
Ischemia — 257.5 133.6 — — 55.8 12.1 48.0 19.0*
Nitric oxide — 298.3 2.9 — 77.0 133.4 187.4 1.6 250.4 25.4†
Off-LAP (mm Hg)
Control 9.4 4.1 12.0 4.3 10.0 1.1 10.9 1.7 10.9 3.8 15.5 2.5
Ischemia 7.9 3.7 11.5 3.2 7.2 9.8 7.9 6.3 10.3 8.2 11.6 4.3
Nitric oxide 7.7 2.6 9.6 1.2 10.3 3.1 8.5 2.8 8.1 5.2 16.8 4.5
Off-LVP (mm Hg)
Control 40.1 10.4 46.8 5.9 40.4 7.8 36.8 9.2 33.2 13.3 42.0 12.4
Ischemia 36.7 3.7 33.5 12.7 18.8 9.9* 12.9 8.5* 20.4 3.5 17.2 3.6*
Nitric oxide 38.2 5.2 49.8 5.4 25.8 10.8 20.2 6.8* 24.1 8.6 33.6 12.3
Off-RAP (mm Hg)
Control 2.0 1.3 2.0 0.8 3.8 2.2 3.7 2.2 5.1 1.5 9.0 5.6
Ischemia 2.2 1.2 2.4 0.6 8.3 7.9 8.3 4.8 9.6 4.8 7.8 6.9
Nitric oxide 1.8 1.8 2.2 0.6 6.4 5.1 6.1 4.8 3.6 2.0† 7.0 2.2
Off-RVP (mm Hg)
Control — 16.7 2.8 18.4 2.7 17.8 2.6 14.8 1.8 17.5 2.4
Ischemia — 13.9 5.9 12.3 5.6 12.5 3.3 14.4 3.4 13.6 3.6
Nitric oxide — 20.8 2.1 13.2 4.9 11.3 3.7 10.9 1.8 18.2 4.1
*P  .05 versus control group.
†P  .05 versus ischemia only group.
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Wet/Dry Ratio of the Lung
The wet/dry ratio of the control group was 5.5  0.4. In the
ischemic groups, the wet/dry ratio for the ischemia group
was higher than that for the nitric oxide group (7.36  1.35
and 6.10  1.49, respectively), but the difference was not
significant. There was a significant difference between the
control group and the ischemia group (P  .05). This result
suggests that addition of nitric oxide inhalation to ischemia
mitigates lung edema that is otherwise easily generated by
the conditions of BVAD support.
Figure 4. Time courses of hemodynamic changes based on native circulation. A, CO. B, Maximum LV dp/dt (LV max
dp/dt). C, LVEDP. D, Maximum RV dp/dt (RV max dp/dt). E, RVEDP. Within observation time (6 hours), recovery of
CO was not observed in ischemia group but was observed in nitric oxide group, in which CO recovered to almost
same grade as control group. Moreover, although LVEDP and RVEDP showed no significant differences in each
group, recoveries of LV dp/dt and RV dp/dt at same grade were observed, without time lag.
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Discussion
Postoperative right ventricular failure is observed in 20% to
30% of patients supported with an LVAD. Although the
need for right ventricular assistance is temporary in many
cases, some patients still require RVAD support because of
inadequate response to vasodilators or other medicines.
Therefore a management strategy for biventricular assis-
tance that includes weaning the patient from RVAD support
is an important issue. Furthermore, whereas common clin-
ical VAD application involves a pulsatile pump, reports on
management strategies for CFBVADs are rare.17-23
To maintain LVAD flow when cardiac function is criti-
cal, such as during Vf, it is generally understood that in-
creasing preload supports LPF. This in turn means that an
increased RPF is a necessary condition in a CFBVAD.
Because increased RVAD flow may induce lung conges-
tion, however, the avoidance of the latter becomes an im-
portant issue in the management of a CFBVAD.24
Meanwhile, nitric oxide inhalation therapy is often used
in patients with pulmonary hypertension or acute respiratory
distress syndrome25,26 for its ability to dilate the pulmonary
vascular bed. Because this process may reduce the operating
frequency of RVAD support, investigators are inquiring
with interest. In this series, inhalation of 40-ppm nitric
oxide reduced PVR and PAP immediately, and it not only
made easy an increase in RVAD flow but also maintained
the circulations of the lungs and body without inducing lung
edema, with the overall result of prompt weaning from
RVAD support.
Nitric oxide inhalation therapy for patients with LVAD
during right heart failure, where the VAD uses a pulsatile
pump, is becoming a comparatively common procedure.
With the attention attracted to the clinical usefulness of the
continuous-flow VAD in recent years, it is inevitable that
combined use of the continuous-flow VAD and nitric will
become known. Whereas nitric oxide inhalation has been
recommended before implantation of an RVAD, nitric ox-
ide inhalation in a case of BVAD implantation has seldom
been examined.28
Some investigators have reported that the small amount
of nitric oxide in coronary blood reduces the induction of
nitric oxide synthase activity and its cytotoxicity in
vitro.29-31 Our results showed that LV dp/dt and RV dp/dt
decreased immediately after global ischemia, and the crea-
tine phosphokinase MB isoenzyme level increased to sim-
ilar degrees in both ischemic groups during the observation
period, suggesting that a similar degree of ischemic myo-
cardial injury was inflicted in both ischemic groups. Al-
though this damage was occasionally fatal, significant re-
covery of cardiac function (to as much as 80% of control
level) was observed in the nitric oxide group.
The fact that there was no time lag between the change
of LV dp/dt and RV dp/dt is encouraging. Nevertheless,
nitric oxide inhalation did not directly affect the right ven-
tricle but only reduced its afterload. On this issue, many
studies have reported that right ventricular function is im-
proved in response to nitric oxide inhalation mainly as a
result of reduced pulmonary resistance, rather than any
change in right ventricular contractility.32,33
RVEDP showed a similar increasing pattern in both
ischemic groups, and it remained at almost same value as
that in the control group except during the ischemic phase.
Nevertheless, LV dp/dt, RV dp/dt, and LVEDP showed
different patterns. This suggests that continuous injection of
TABLE 3. Oxygen consumption versus SvO2
Group Baseline VAD set 1 h 2 h 3 h 4 h 5 h 6 h
Control




0.26 0.18 0.27 0.08 0.29 0.09 0.37 0.12 0.37 0.09 0.39 0.06 0.39 0.04 0.4 0.03
Ischemia
only




0.20 0.05 0.27 0.06 0.32 0.09 0.30 0.07 0.32 0.10 0.37 0.09 0.39 0.04 0.42 0.14
Nitric oxide




0.16 0.06 0.24 0.03 0.29 0.06 0.27 0.07 0.29 0.08 0.30 0.07 0.36 0.10 0.36 0.07









*Oxygen extraction ratio calculated as oxygen consumption (in milliliters per minute)/oxygen supply (in milliliters per minute).
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Ringer’s lactate solution led to similar preloads in the
groups and did not directly affect the function of the right
side of the heart.
Because these differences were observed independent of
the pump flows (which were maintained at similar levels in
all groups), the possibility of a cardioprotective effect of NO
inhalation therapy is suggested. However, because the de-
gree of cardioprotective effect for cardiomyocytes could not
be examined in our experiment by either a histologic or a
tissue dynamic approach, we can only introduce the possi-
bility and provide references.27,34-36
In this series, PAP increased after global ischemia.
About this point, some facts should be observed. In the
preceding experiment, despite increased LVAD speed, just
before ventricular collapse occurred, it tended to be difficult
to secure LVAD flow after global ischemia to maintain
body circulation. To maintain LPF, security of the RPF was
indispensable as preload of LVAD. However, despite in-
creased RVAD speed just before atrial collapse occurred, it
tended to be difficult to secure sufficient RPF after global
ischemia. In this series, continuous injection of Ringer’s
lactate solution was performed to secure preload of the
RVAD. For this reason, the RPF tend to increase a little
after global ischemia.
On the other hand, although there was no significant
difference between each group, Pao2 showed some decrease
in all cases at equipping BVAD and when reddening of
lungs was observed in the ischemia group after global
ischemia. Because of these findings, a possibility that acute
respiratory distress syndrome was induced at these period
was also considered. However, in this series the clear pa-
rameter change proving existence of acute respiratory dis-
tress syndrome was not observed. Thus it is thought that
PAP was increased after global ischemia according to these
complex causes.
Moreover, the pattern of weaning from RVAD support
by NO inhalation observed in this series may be transient,
and this study does not exclude the possible existence of a
rebound effect. To evaluate these concerns, this research is
expected to be pursued in a longer term experiment.
Although various adverse effects of nitric oxide on pa-
tients and the environment have been reported,25-27 no ad-
verse effects of nitric oxide inhalation, such as methemo-
globinemia, were demonstrated in this series. Moreover,
despite some reports that lung edema is induced by nitric
oxide inhalation in healthy adults, there was no lung edema
in the nitric oxide inhalation group in this experimental
series. Rather, lung edema induced through CFBVAD sup-
port in the ischemic groups was improved by inhalation of
nitric oxide. Thus we consider nitric oxide inhalation to
reduce PVR, allowing a smoother lung circulation.
Incidentally, in this series spontaneous urination was
observed in the nitric oxide group but not in the control
group. Although assessment of this phenomenon is some-
what difficult, we believe that maintenance of the microcir-
culation of the urinary system leads to preservation of the
voiding system.
From these results, the following hypothetical strategies
are presumed to aid in the medical treatment of severe heart
failure. In severe heart failure that requires strict mechanical
support, to plan sufficient unloading of the whole myocar-
dium, a patient should be equipped not only with LVAD but
also with RVAD from an initial stage. However, in a post-
operative early stage, in the state with the inadequate con-
tractility of the heart, such as the Vf and weak contraction
phases observed in this series, because RPF has to be
increased for LPF reservation, nitric oxide inhalation from
an early stage is used to reduce PVR. Sufficient unloading
without lung edema by BVAD support becomes possible,
and recovery of the cardiac function is promoted as a result.
With recovery of the heartbeat, when sufficient output of
right side circulation can be secured, weaning from the
RVAD is started.
Although the RVAD was deployed through a thoracot-
omy in this study, taking into consideration the promotion
of weaning from RVAD support expected through inhala-
tion of nitric oxide, temporary right heart assistance may be
achievable by a percutaneous approach.37-39 Although such
equipment is devised to lessen operation stress by inserting
cannula percutaneously into the right side circulation, the
limitation of the flow depending on the diameter of cannula
or the danger of the infection with long-term use are re-
garded as questionable.
Considering the possibility of the reduced RVAD flow
and shortened supporting period by nitric oxide inhalation,
it is thought that we can chose these mechanical support
devices as one of the medical treatment strategies. An
evaluation of this situation is expected in the course of
future research.
Conclusion
In an acute, severe biventricular failure porcine model,
nitric oxide inhalation under CFBVAD support significantly
decreased PVR and reduced the afterload of the right ven-
tricle. Consequently, the blood volume of the cardiopulmo-
nary circulation under CFBVAD plus nitric oxide support
increased without lung edema. Nitric oxide inhalation ther-
apy has the potential to enable weaning from continuous
flow RVAD support of animals with severe heart failure
necessitating CFBVAD.
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